With FOXO1 not only as the endpoint of IGF signaling but also of insulin signaling via the PI3K-AKT pathway, we focused our investigations on the metabolic effects of apigenin and luteolin to analyze their roles in modulating insulin signal transduction which is disturbed in insulin resistance and T2D. Here, FOXO1 is linked to type 2 diabetes mellitus.